Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

9.7K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.7K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

3.4K
3.4K
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

335
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
335
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

638
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
638
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

413
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
413
Formation of Muscle Fibers from Myoblasts01:13

Formation of Muscle Fibers from Myoblasts

5.7K
De novo myogenesis, or the formation of muscle fibers, begins during the early embryonic stages. The skeletal muscle is formed from somites– blocks of embryonic cell layers. The somites are further divided into dermatomes, myotomes, sclerotomes, and syndetomes. Among these, the myotomes give rise to muscle fibers.
Muscle progenitor cells (MPCs) are formed from the myotomes. MPCs express genes that encode the transcription factors Pax3 and Pax7. Along with Pax 3/7, other transcription...
5.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[<i>Wenshen Yanggan</i> Decoction improves intestinal function in mouse models of Parkinson's disease by regulating intestinal bioactive substances].

Nan fang yi ke da xue xue bao = Journal of Southern Medical University·2026
Same author

Efficacy and safety of Shenqi Yangxin formula in patients with stable coronary artery disease based on CCTA: rationale, design, and study protocol for a randomized, double-blind, placebo-controlled study.

Frontiers in cardiovascular medicine·2026
Same author

Solvent-Regulated Enantiodivergent Construction of Secondary Phosphine Oxides with P-Stereogenicity.

Organic letters·2026
Same author

Shenfu decoction attenuates radiation-induced heart disease by modulating the P53-MDM2 complex and the STAT1-BATF2 axis.

Phytomedicine : international journal of phytotherapy and phytopharmacology·2026
Same author

The TRIM27/STING Axis Mediates Schisandrin B-Induced Inhibition of Myeloid-Derived Suppressor Cells Accumulation to Potentiate Anti-PD-1 Immunotherapy in Hepatocellular Carcinoma.

Phytotherapy research : PTR·2026
Same author

10-Gingerol induces ferroptosis via TFEB-mediated NRF2 lysosomal degradation in NSCLC.

Toxicology and applied pharmacology·2026
Same journal

Overcoming barriers to early diagnosis and treatment of p.Val142Ile amyloid transthyretin (ATTR) cardiomyopathy.

Heart failure reviews·2026
Same journal

Beyond vasodilation: sotatercept and the remodeling hypothesis in hfpef-associated pulmonary hypertension.

Heart failure reviews·2026
Same journal

Beyond the right ventricle: left heart involvement in pulmonary arterial hypertension.

Heart failure reviews·2026
Same journal

Left ventricular non-compaction in heart failure: contemporary perspective on diagnostic challenges and treatment opportunities.

Heart failure reviews·2026
Same journal

Correction to: Left atrial shunting devices: why, what, how, and… when?

Heart failure reviews·2026
Same journal

Cardiac microcurrent therapy in heart failure: Mechanistic rationale, early clinical evidence, and future directions.

Heart failure reviews·2026
See all related articles

Related Experiment Video

Updated: Jan 4, 2026

Tissue-specific miRNA Expression Profiling in Mouse Heart Sections Using In Situ Hybridization
08:22

Tissue-specific miRNA Expression Profiling in Mouse Heart Sections Using In Situ Hybridization

Published on: September 15, 2018

8.5K

Long non-coding RNAs in cardiac hypertrophy.

Jinghui Sun1, Chenglong Wang2

  • 1Cardiovascular Disease Research Center, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Haidian District, Beijing, 100091, China.

Heart Failure Reviews
|October 31, 2019
PubMed
Summary
This summary is machine-generated.

Cardiac hypertrophy (CH) involves adaptive responses that can progress to heart failure (HF). Long non-coding RNAs (lncRNAs) are increasingly recognized as key regulators in CH, offering novel therapeutic targets.

Keywords:
Cardiac hypertrophyCardiac remodelingHeart failureLong non-coding RNAs

More Related Videos

Technique of Minimally Invasive Transverse Aortic Constriction in Mice for Induction of Left Ventricular Hypertrophy
08:34

Technique of Minimally Invasive Transverse Aortic Constriction in Mice for Induction of Left Ventricular Hypertrophy

Published on: September 25, 2017

25.3K
An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level
06:02

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level

Published on: November 2, 2020

6.1K

Related Experiment Videos

Last Updated: Jan 4, 2026

Tissue-specific miRNA Expression Profiling in Mouse Heart Sections Using In Situ Hybridization
08:22

Tissue-specific miRNA Expression Profiling in Mouse Heart Sections Using In Situ Hybridization

Published on: September 15, 2018

8.5K
Technique of Minimally Invasive Transverse Aortic Constriction in Mice for Induction of Left Ventricular Hypertrophy
08:34

Technique of Minimally Invasive Transverse Aortic Constriction in Mice for Induction of Left Ventricular Hypertrophy

Published on: September 25, 2017

25.3K
An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level
06:02

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level

Published on: November 2, 2020

6.1K

Area of Science:

  • Cardiology
  • Molecular Biology
  • Genetics

Background:

  • Cardiac hypertrophy (CH) is an adaptive response to cardiac stress, but prolonged stimulation can lead to heart failure (HF).
  • The precise molecular mechanisms underlying CH remain incompletely understood.
  • Long non-coding RNAs (lncRNAs) have emerged as critical players in cardiovascular diseases.

Purpose of the Study:

  • To explore the role of lncRNAs in the molecular mechanisms of cardiac hypertrophy.
  • To identify potential therapeutic targets for CH based on lncRNA regulation.

Main Methods:

  • Literature review and analysis of recent evidence on lncRNAs in CH.
  • Investigating the diverse mechanisms by which lncRNAs influence CH progression.
  • Examining the potential for lncRNA expression modulation to treat CH.

Main Results:

  • Evidence indicates that various lncRNAs significantly impact CH.
  • Different lncRNAs exert opposing effects, either promoting or inhibiting CH.
  • Modulating lncRNA expression shows promise in ameliorating CH.

Conclusions:

  • lncRNAs are pivotal in the pathogenesis of cardiac hypertrophy.
  • Targeting lncRNAs represents a promising novel therapeutic strategy for CH.
  • Further research into CH-related lncRNAs is warranted.